Marit M van Buuren
Overview
Explore the profile of Marit M van Buuren including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
7195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgers J, Lenkala D, Kohler V, Jackson E, Linssen M, Hymson S, et al.
Nat Med
. 2025 Jan;
PMID: 39753970
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived...
2.
Choi J, Goulding S, Conn B, McGann C, Dietze J, Kohler J, et al.
Cell Rep Methods
. 2022 Apr;
1(5):100084.
PMID: 35474673
Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell...
3.
Wells D, van Buuren M, Dang K, Hubbard-Lucey V, Sheehan K, Campbell K, et al.
Cell
. 2020 Oct;
183(3):818-834.e13.
PMID: 33038342
Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However, there are no reference data to compare these approaches,...
4.
Poran A, Harjanto D, Malloy M, Arieta C, Rothenberg D, Lenkala D, et al.
Genome Med
. 2020 Aug;
12(1):70.
PMID: 32791978
Background: The ongoing COVID-19 pandemic has created an urgency to identify novel vaccine targets for protective immunity against SARS-CoV-2. Early reports identify protective roles for both humoral and cell-mediated immunity...
5.
van den Berg J, Heemskerk B, van Rooij N, Gomez-Eerland R, Michels S, van Zon M, et al.
J Immunother Cancer
. 2020 Aug;
8(2).
PMID: 32753545
Purpose: Execute a phase I/II feasibility study with TIL therapy in metastatic melanoma at the Netherlands Cancer Institute, with the goal to assess feasibility and potential value of a randomized...
6.
Kroon P, Frijlink E, Iglesias-Guimarais V, Volkov A, van Buuren M, Schumacher T, et al.
Cancer Immunol Res
. 2019 Feb;
7(4):670-682.
PMID: 30782666
To increase cancer immunotherapy success, PD-1 blockade must be combined with rationally selected treatments. Here, we examined, in a poorly immunogenic mouse breast cancer model, the potential of antibody-based immunomodulation...
7.
Linnemann C, van Buuren M, Bies L, Verdegaal E, Schotte R, Calis J, et al.
Nat Med
. 2016 Oct;
22(10):1192.
PMID: 27711057
No abstract available.
8.
Verdegaal E, de Miranda N, Visser M, Harryvan T, van Buuren M, Andersen R, et al.
Nature
. 2016 Jun;
536(7614):91-5.
PMID: 27350335
Recognition of neoantigens that are formed as a consequence of DNA damage is likely to form a major driving force behind the clinical activity of cancer immunotherapies such as T-cell...
9.
Stronen E, Toebes M, Kelderman S, van Buuren M, Yang W, van Rooij N, et al.
Science
. 2016 May;
352(6291):1337-41.
PMID: 27198675
Accumulating evidence suggests that clinically efficacious cancer immunotherapies are driven by T cell reactivity against DNA mutation-derived neoantigens. However, among the large number of predicted neoantigens, only a minority is...
10.
Antigen-specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy
Kelderman S, Heemskerk B, Fanchi L, Philips D, Toebes M, Kvistborg P, et al.
Eur J Immunol
. 2016 Mar;
46(6):1351-60.
PMID: 27005018
Tumor infiltrating lymphocyte (TIL) therapy has shown objective clinical response rates of 50% in stage IV melanoma patients in a number of clinical trials. Nevertheless, the majority of patients progress...